![](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F228216%2F730a3bd85d%2Fnovo-holdings-portfolio-company-vectivbio-goes-public.jpg&w=3840&q=75)
![](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F228216%2F730a3bd85d%2Fnovo-holdings-portfolio-company-vectivbio-goes-public.jpg&w=3840&q=75)
News
April 13, 2021
Novo Holdings’ portfolio company VectivBio goes public
Novo Ventures, the ventures arm of Novo Holdings, is pleased to note the $146.6 million Initial Public Offering on NASDAQ of its portfolio company VectivBio Holdings AG [VECT]. VectivBio is a Swiss company focused on the development of Apraglutide, a next-generation, long-acting, synthetic GLP-2 analog for short bowel syndrome, currently in Phase 3 clinical development.
For further information, please find the full statement here.